CRISPR Therapeutics (CRSP) PT Lowered to $101 at Stifel
Tweet Send to a Friend
Stifel analyst Benjamin J. Burnett lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $101.00 (from $139.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE